Parkinson Disease
📧 Sign up to get email alerts when something new happens for Parkinson Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-03-27Clinical Trial Update: Deep Neural Network Approaches for Closed-Loop Deep Brain Stimulation [NA]
The study 'Deep Neural Network Approaches for Closed-Loop Deep Brain Stimulation' sponsored by Massachusetts General Hospital has been withd…
-
CLINICAL_TRIALS withdrawal · 2026-03-24Clinical Trial Update: Context- and Terrain-aware Gait Analysis
A University of Leeds clinical trial evaluating context- and terrain-aware gait analysis in Parkinson's disease, dementia, and related condi…
-
CLINICAL_TRIALS withdrawal · 2026-03-12Clinical Trial Update: Essential Amino Acids and Parkinsons Disease [Phase 1]
A Phase 1 clinical trial investigating essential amino acids for Parkinson disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-10-21Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes [Phase 2]
Phase 2 trial evaluating Staccato Apomorphine (AZ-009) for Parkinson's disease patients experiencing OFF episodes has been terminated.
-
CLINICAL_TRIALS withdrawal · 2025-09-19Clinical Trial Update: Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA [Phase 2]
A Phase 2 study exploring meditation effects on brain activity in Parkinson disease using FDOPA imaging has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-08-22Clinical Trial Update: Dynamic Motor Cortical Responses to Subdural Electrical Stimulation. [NA]
A clinical trial evaluating dynamic motor cortical responses to subdural electrical stimulation for Parkinson's disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-07-24Clinical Trial Update: Effect of Rasagiline on Balance in Parkinson's Disease as Measured by Computerized Posturography [Phase 4]
The Phase 4 clinical trial evaluating rasagiline on balance in Parkinson's disease has been withdrawn; no results are reported.
-
CLINICAL_TRIALS withdrawal · 2025-06-22Clinical Trial Update: Clinical Investigation of NMS Assist [NA]
The clinical investigation of NMS Assist for Parkinson's disease has been withdrawn. The study, sponsored by the University of Plymouth, is …
-
CLINICAL_TRIALS withdrawal · 2025-06-05Clinical Trial Update: A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease
A pilot study from ProgenaBiome investigating the role of gut flora in Parkinson's disease has been withdrawn.
-
EMA withdrawal · 2025-03-28EMA Lapsed: Ontilyv (opicapone) — Bial Portela & Companhia S.A.
EMA has lapsed the marketing authorization for Ontilyv (opicapone) by Bial Portela & Companhia S.A. for Parkinson disease; the lapse is effe…
-
CLINICAL_TRIALS withdrawal · 2025-03-19Clinical Trial Update: Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study [Phase 2]
A Phase 2 trial of Valiloxybate (XW10172 MR) for Parkinson disease with Excessive Daytime Somnolence has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-03-19Clinical Trial Update: Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)
A clinical trial investigating early diagnosis of Parkinson's disease by detecting alpha-synuclein aggregates using PMCA has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-03-13Clinical Trial Update: Theophylline Nasal Spray for PD-Related Hyposmia and Anosmia [Phase 1]
Phase 1 trial of theophylline nasal spray for Parkinson's disease-related hyposmia and anosmia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-01-07Clinical Trial Update: Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease [Phase 2, Phase 3]
A Phase 2/3 trial of rasagiline for prodromal Parkinson disease, including REM sleep behavior disorder, has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-01-07Clinical Trial Update: A Study of Efficacy and Safety of Idebenone Vs. Placebo in Prodromal Parkinson Disease [Phase 2, Phase 3]
A study evaluating idebenone versus placebo in prodromal Parkinson disease and REM sleep behavior disorder has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-12-20Clinical Trial Update: Pimavanserin for Sleep in Parkinson Disease [EARLY_Phase 1]
A clinical trial evaluating pimavanserin for sleep disturbances in Parkinson's disease was withdrawn (early-phase 1).
-
CLINICAL_TRIALS withdrawal · 2024-10-15Clinical Trial Update: Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease [NA]
A clinical trial evaluating vibrational therapy to improve gait and balance in Parkinson's disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-10-02Clinical Trial Update: Inpatient Physical Activity Function Through Enhanced Participation Levels in Animal-Assisted Therapy Programs [NA]
A clinical trial evaluating inpatient physical activity function through enhanced participation in animal-assisted therapy for stroke and Pa…
-
CLINICAL_TRIALS withdrawal · 2024-08-12Clinical Trial Update: An Open-label Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Deep Brain Stimulation [NA]
An open-label clinical trial comparing adaptive versus conventional deep brain stimulation for Parkinson's disease has been withdrawn. Spons…
-
CLINICAL_TRIALS withdrawal · 2024-07-03Clinical Trial Update: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) [Phase 2]
The Phase 2 study CLIN-012 evaluating CST-103 co-administered with CST-107 in Parkinson's disease patients with freezing of gait has been wi…
-
EMA withdrawal · 2024-03-11EMA Withdrawn: Pramipexole Accord (pramipexole dihydrochloride monohydrate) — Accord Healthcare S.L.U.
Withdrawn EMA decision for Pramipexole Accord (pramipexole dihydrochloride monohydrate) by Accord Healthcare S.L.U., affecting Parkinson's d…
-
CLINICAL_TRIALS withdrawal · 2023-01-20Clinical Trial Update: Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure [Phase 3]
Phase 3 trial of TD-9855 for symptomatic neurogenic orthostatic hypotension was terminated; results were posted in 2023.
-
CLINICAL_TRIALS withdrawal · 2022-04-14Clinical Trial Update: Study of Zonisamide in Early Parkinson Disease [Phase 2, Phase 3]
A phase 2/3 trial evaluating zonisamide in early Parkinson disease has been withdrawn.
-
EMA withdrawal · 2022-02-18EMA Withdrawn: Leganto (rotigotine) — UCB Pharma S.A.
Leganto (rotigotine) has been withdrawn from the market by UCB Pharma S.A., affecting treatment areas including restless legs syndrome and P…
-
CLINICAL_TRIALS withdrawal · 2021-11-16Clinical Trial Update: Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease [Phase 4]
A Phase 4 trial of Keppra IV for motor fluctuations in Parkinson's Disease was withdrawn.